Home › Illumina Secures CE Mark for VeriSeq NIPT

Illumina Secures CE Mark for VeriSeq NIPT

Apr 10, 2017

NEW YORK (GenomeWeb) – Illumina announced today that it has launched its noninvasive prenatal test, VeriSeq NIPT, as a CE-marked in vitro diagnostic in Europe. The test screens for trisomies 21, 18, and 13, as well as some sex chromosomal disorders at 10 weeks' gestation.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Aug
27
Featured Webinar

Case Study: Genetic Testing Lab Sees 25-Fold Scaleup with New Informatics System

Sponsored by
Qiagen

This webinar offers a look at how an advanced genetics laboratory implemented and validated a commercial bioinformatics system to help scale its operations.

Sep
17
Featured Webinar

Trends in Clinical NGS QC Management: Expert Insights to Ensure Quality Results for Your Lab

Sponsored by
SeraCare

Today’s challenging clinical next-generation sequencing applications require a rigorous, comprehensive quality control management program to ensure confidence in results.

What's Popular?

In Molecular Diagnostics

  1. China FDA Approves Novogene CDx Test for NSCLC Therapies

  2. Cell-Free DNA Screening, Invasive Testing Show Similar Miscarriage Rates, Study Suggests

  3. Natera Partners With Fox Chase to Evaluate ctDNA Cancer Assay

  4. OnSiteGene Developing Ultra-Fast qPCR System for Rapid Syndromic Testing

    Premium

  5. Genetic Technologies Announces Planned Chinese Joint Venture

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.